BioXcel Therapeutics reports Q4 EPS ($3.57), consensus ($5.14)

Reports Q4 revenue $366k, consensus $718.26k. “We believe that our SERENITY program presents an exciting opportunity to address a substantial unmet medical need – the 23 million episodes of bipolar and schizophrenia-related agitation that occur annually in the United States at home – and expand the market potential for our lead neuroscience asset BXCL501,” said Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics (BTAI). “We are pleased that patient enrollment in our SERENITY At-Home pivotal Phase 3 trial is progressing well and that we have recently strengthened our cash position to further advance this important study.”